ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Surgical Management of Both Stage III and Stage IV Pulmonary Carcinoid Tumors Confers Survival Benefit

Thursday, August 7, 2025

Submitted by

Source

Source Name: Journal of Thoracic and Cardiovascular Surgery Open

Author(s)

J. Asher Jenkins, Pedro Augusto Reck Dos Santos, Zhong Gu, Matthew Buras, Juan M. Farina, Nathan Y. Yu, Yanmei Peng, Jason Wampfler, Cecilia Benz, Vinicius Ernani, Jonathan D'Cunha, Stephen D. Cassivi, Ping Yang

This large, retrospective study (1997–2023) found that surgical resection offers a significant survival benefit for both stage III and stage IV pulmonary carcinoid tumors, including those with metastatic disease. Surgery reduced mortality risk in both stages, regardless of histologic subtype, and survival rates were similar after lobectomy or sublobar resection. Atypical histology and the presence of multiple metastases were associated with worse outcomes. Chemotherapy and radiotherapy did not provide additional survival benefits. These findings, supported by SEER database analyses, suggest that surgery should be considered even for advanced-stage or metastatic pulmonary carcinoid tumors, challenging current conservative guidelines. 

Add comment

Log in or register to post comments